Drugs in France: usage levels, risks, and prevention responses
Partager
What do the most recent French data show?
According to the 2023 EROPP survey by the French Observatory of Drugs and Addictive Behaviors, more than half of adults aged 18 to 64 report having used cannabis at least once in their lifetime. However, use within the year remains significantly less frequent and stable nationwide.
Experimentation levels with other illicit drugs have increased since 2017, especially for stimulants. Nearly one in ten adults reports having used powdered cocaine, and about one in twelve has used MDMA at least once.
What are the main risks?
- Acute risks: fainting, loss of consciousness, agitation, heart problems, overdose, accidents, or dangerous behavior.
- Risks related to combinations: alcohol, sedative medications, opioids, or stimulants can amplify or mask each other’s effects.
- Medium and long-term risks: addiction, mental disorders, neurological, respiratory, or cardiovascular damage depending on the substances and methods of use.
- Social and professional risks: accidents, conflicts, financial difficulties, dropping out of school, or job loss in the most severe cases.
The level of danger varies greatly. A substance described as “natural,” “festive,” or “legal” is not necessarily risk-free. Conversely, a person who uses should not be reduced to their use nor stigmatized.
Why do current products require more vigilance?
Markets are evolving rapidly: more concentrated products, new synthetic molecules, tablets or powders of uncertain composition, and sales facilitated by digital networks. The appearance of a product never reveals its composition or dosage.
What responses are truly effective?
- precise information, adapted to age and context;
- early prevention without moralizing discourse;
- harm reduction for people who use;
- access to Youth Consumer Consultations and CSAPA;
- training for professionals, supervisors, and event organizers;
- supervised testing when legal context and safety justify it.
What role do screening tests play?
A rapid test can provide an indication of one or more targeted substances. It does not detect all molecules, does not automatically measure the degree of impairment, and does not replace laboratory toxicological analysis.
In the workplace, on the road, in medical or family settings, its interpretation and consequences differ. Prevention should never be limited to testing: it must also inform, protect, and guide toward appropriate help.
